EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Tumor-microenvironment-mediated immune escape drives trastuzumab resistance in HER2-positive gastric cancer

Huifang Lv, Wanying Zhao, Sai-Qi Wang, Yunduan He, Caiyun Nie, Xiao-Bing Chen

Gastroenterology Report · 20.01.2026 · 14

DOI: 10.1093/gastro/goag068 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Gastroenterology Report, online erschienen am 31.07.2026. Verfasst von Huifang Lv und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Henan Province Engineering Research Center fo…. Die Arbeit nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The combination of trastuzumab and chemotherapy, with or without pembrolizumab, is the current first-line standard of care for patients with human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer and gastroesophageal junction cancer. However, upon disease progression, subsequent therapies often yield limited clinical benefit. The mechanisms of drug resistance to trastuzumab remain unresolved. Current studies on its resistance mechanisms have largely focused on alterations in the HER2 pathway, including HER2 heterogeneity, reduced or absent HER2 expression, variations in HER2 dimerization, and mutations in downstream components, among others. Crucially, as a monoclonal antibody, the antitumor activity of trastuzumab is partially mediated by the immune system, yet the immunology-related mechanisms of resistance are frequently overlooked. In this review, we systematically analyse the outcomes of both successful and failed clinical trials of anti-HER2 agents to propose that immune escape within the tumor microenvironment is a key driver of trastuzumab resistance in HER2-positive gastric cancer.

Schlagwörter

Stichwörter der Autor:innen

HER2drug resistancegastric cancertrastuzumab

Autor:innen und Institutionen

  • Department of Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Henan Province Engineering Research Center for of Intractable Digestive Tract Tumor Precision Therapy, Henan Provin…
  • State Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, Zhengzhou University, Zhengzhou 450052, Henan, P. R. China.
  • Cancer Hospital, The First Affiliated Hospital (College of Clinical Medicine), Henan University of Science and Technology, Luoyang 471003, Henan, P. R. China.

Zitieren

APA

Lv, H., Zhao, W., Wang, S. Q., He, Y., Nie, C., & Chen, X. B. (2026). Tumor-microenvironment-mediated immune escape drives trastuzumab resistance in HER2-positive gastric cancer. Gastroenterology Report, 14. https://doi.org/10.1093/gastro/goag068

Vancouver

Lv H, Zhao W, Wang SQ, He Y, Nie C, Chen XB. Tumor-microenvironment-mediated immune escape drives trastuzumab resistance in HER2-positive gastric cancer. Gastroenterology Report. 2026;14. doi:10.1093/gastro/goag068

BibTeX
@article{Lv2026,
  author = {Lv, Huifang and Zhao, Wanying and Wang, Sai-Qi and He, Yunduan and Nie, Caiyun and Chen, Xiao-Bing},
  title = {Tumor-microenvironment-mediated immune escape drives trastuzumab resistance in HER2-positive gastric cancer},
  journal = {Gastroenterology Report},
  year = {2026},
  volume = {14},
  doi = {10.1093/gastro/goag068}
}
Kostenlos starten →